Related Experiment Video
Updated: Jul 11, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Alzheimer's disease as copper deficiency
1Departments of Internal Medicine and of Pharmacology, Physiology and Therapeutics, Grand Forks, ND 58201, United States. leslie_klevay@und.nodak.edu
Medical Hypotheses
|October 12, 2007
Summary
Copper deficiency may cause Alzheimer's disease (AD). Research links low copper to AD brain changes, cognitive decline, and increased tau. Further trials are needed to confirm copper supplementation as a treatment.
Area of Science:
- Neuroscience
- Nutritional Science
- Pathology
Background:
- Alzheimer's disease (AD) research often overlooks etiologic causes, focusing on pathogenesis.
- Low copper and cytochrome oxidase levels are observed in the brains of AD patients.
- Nutritional factors, specifically copper intake, are underexplored in AD etiology.
Purpose of the Study:
- To investigate the hypothesis that copper deficiency is a plausible cause of Alzheimer's disease.
- To explore the link between copper status and key AD biomarkers and cognitive function.
- To evaluate the potential of copper supplementation as an intervention for AD.
Main Methods:
- Review of existing research on copper's role in neurological processes.
- Analysis of animal studies involving copper deficiency and related pathologies (amyloid, oxidative defense).
- Correlation of decreased cognition and increased tau in cerebrospinal fluid with low copper status in AD patients.
Main Results:
- Animal experiments with copper deficiency show parallels with AD pathology, including issues with amyloid and oxidative defense.
- Low copper status is associated with cognitive decline and elevated tau levels in cerebrospinal fluid.
- A high copper requirement may explain early-onset AD in Down's syndrome.
Conclusions:
- Copper deficiency presents a plausible causal link to Alzheimer's disease.
- Further investigation through extensive copper supplementation trials is warranted.
- Addressing copper status could be a novel therapeutic strategy for AD.
More Related Videos
06:52Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...